- Active not recruitingPHASE2
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients
This study looks at a lung cancer drug called lorlatinib for people with a specific type of non-small cell lung cancer (NSCLC) where previous treatments have stopped working. It aims to see if specific changes in the cancer's genes, found in blood tests, can predict who will benefit most from lorlatinib.
For: Non Small Cell Lung CancerBelgium · France · Jordan - Active not recruitingPHASE3
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
This study compares two drugs, lorlatinib and crizotinib, for people with a specific type of advanced lung cancer called ALK-positive NSCLC. It aims to see if lorlatinib works better at stopping the cancer from growing for longer. This is for patients who haven't had previous treatment for their advanced cancer.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia